Adamas Corporate Development Strategy

We are considering all corporate development opportunities, including partnering, consistent with our corporate strategies to develop and commercialize differentiated medicines for patients with chronic neurologic disorders.

To learn more about partnering opportunities with Adamas, please click here to contact us.

Ongoing Partnership

Through a partnership with Allergan, our portfolio includes two drugs commercially available in the United States for the treatment of moderate to severe dementia of the Alzheimer’s type: NAMENDA XR® (memantine hydrochloride) extended-release capsules and NAMZARIC® (memantine hydrochloride extended-release and donepezil hydrochloride) capsules.

Additionally through our license agreement to Allergan, the company is eligible to receive royalties on sales of NAMENDA XR® and NAMZARIC® beginning in June of 2018 and May of 2020, respectively.

NAMENDA XR® and NAMZARIC® are registered trademark of Merz Pharma GmbH & Co. KGaA.